Kobayashi Minoru, Suzuki Kazumi, Yashi Masahiro, Yuzawa Masayuki, Takayashiki Norio, Morita Tatsuo
Department of Urology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan.
Anticancer Res. 2007 Mar-Apr;27(2):1137-41.
Although renal cell carcinoma (RCC) is considered to be an immunogenic tumor, the role of immunogenicity in this tumor for predicting treatment response has been little investigated.
Resected RCC specimens from 25 patients who received cytokine treatment for metastases were investigated using immunohistochemistry for CD83+ or S100+ dendritic cells (DCs), CD8+ T-cells, HLA-DR+ tumor cells, CD68+ tumor associated macrophages, microvascular density and vascular endotherial growth factor.
Among the examined parameters, DCs status showed predictive value, that is, higher numbers of CD83+ or S100+ cells in tumors were associated with favorable treatment response. However, only higher CD83 status, which indicates mature and activated DCs, contributed to better survival (p = 0.0339).
Increased tumor infiltration of mature DCs would be a predictor of treatment response and outcome in metastatic RCC patients, who receive immunotherapy.
尽管肾细胞癌（RCC）被认为是一种免疫原性肿瘤，但免疫原性在该肿瘤中对预测治疗反应的作用鲜有研究。
对25例接受细胞因子治疗转移灶的患者切除的RCC标本进行免疫组织化学检测，以检测CD83+或S100+树突状细胞（DCs）、CD8+ T细胞、HLA-DR+肿瘤细胞、CD68+肿瘤相关巨噬细胞、微血管密度和血管内皮生长因子。
在所检测的参数中，DCs状态显示出预测价值，即肿瘤中CD83+或S100+细胞数量较多与良好的治疗反应相关。然而，只有较高的CD83状态（表明成熟和活化的DCs）有助于更好的生存（p = 0.0339）。
成熟DCs肿瘤浸润增加将是接受免疫治疗的转移性RCC患者治疗反应和预后的预测指标。
Zotero 插件